Search
Sign up for Email newsletter

Receive regular updates on the latest industry news and events

How We Can Support the Drug Development Pipeline

SNP Genotyping

Description

Single Nucleotide Polymorphisms are bi-allelic, single base-pair changes between the DNA sequences of an individual. They can confer susceptibility or resistance to drug therapies and disease, and a number of SNPs are known to affect drug metabolism and clearance of drug from the body. As such, SNPs may cause toxic build up of drugs and abberant drug reactions.They may also be the cause of non response to a drug and are therefore important to detect to ensure that the best possible treatment is given to the patient. Source BioScience is a preferred service provider for Applied Biosystems TaqMan® and a UK reference lab for Roche AmpliChip® to support research studies and clinical trials. We can also offer Affymetrix and SNP chip analysis.

Applications

 

Applied Biosystems TaqMan® SNP Genotyping

Description

Using Applied BioSytems TaqMan technology, SourceBioScience has access to over 1.2M pre-designed TaqMan assays in 15 species for quantitative gene expression analysis.

Application

The special virtues of SNPs for genetic analysis are their ease of discovery and assay, and their ease of analysis. Their high density in the human genome and their effects, in some cases, on transcription and translation make SNPs valuable for association studies.

The TaqMan ® platform is suitable for projects of 10s of SNPs and 1000s of Samples. For higher throughput projects customers should consider SNPlex.

Top

Applied Biosystems SNPlex ™ 48-plex SNP genotyping system

Description

Single Nucleotide Polymorphisms (SNPS) can exist within a population at any frequency although those with a frequency above 20% are generally most useful in genetic mapping studies.

SNPs are found throughout the genome averaging one SNP every 500 to 1000bp. They can affect translation and transcription. In some circumstances they lead to profound disease whereas elsewhere will have no obvious effect. SNPs are also important in predicting response to therapeutics. Using SNP mutation analysis can enrich patient populations for clinical trials providing the drug development team with meaningful data.

The SNPlex ™ Genotyping System uses an Applied Biosystems oligonucleotide ligation assay (OLA) combined with multiplex PCR technology to achieve allelic discrimination and target amplification.

Source BioScience is an approved service provider for Applied Biosystems SNPlex system

Application

The special virtues of SNPs for genetic analysis are their ease of discovery and assay, and their ease of analysis. Their high density in the human genome and their effects, in some cases, on transcription and translation make SNPs valuable for association studies. The SNPlex platform is ideal for use in screening candidate genes for associations or for confirming genome-wide associations in follow-up populations.

SNPlex studies are of the order of 100s of SNPs genotyped in 1000s of DNA samples. For lower throughput projects customers should consider TaqMan.

Platform

  • MATRIX PlateMatePlus for high throughput liquid handling.
  • SNPlex 48-plex SNP genotyping system for simultaneously assay of large numbers of SNPs.
  • Applied Biosystems GeneAmp PCR system 9700, and MJ Research PTC-225 tetrad - PCR.
  • Applied Biosystems 3730XL DNA analyser.
  • GeneMapper v4.0 from Applied Biosystems.

Use Source BioScience because we can provide:

  • Quality: Rapid turnaround and accurate results. All data is sent in strictest confidence to you on CD-ROM, e-mail or web server.
  • Pricing: Our high throughput reduces unit labour and capital costs meaning we can offer exceptional value for money. Furthermore, savings are made by bulk purchase of reagents and discount deals with suppliers.
  • Commitment to improvement: We constantly review and implement new technologies to reduce costs, shorten timelines and reduce consumables including amounts of your DNA.

Top

RocheRoche

Roche AmpliChip®

The Roche AmpliChip® platform is the first pharmacogenetic microarray-based test approved for clinical use.
The AmpliChip® CYP450 test identifies a patient's genotype by analysing CYP2D6 and CYP2C19, two genes in the cytochrome P450 system that can greatly influence drug metabolism. These two genes code for enzymes that metabolise many antidepressants, antipsychotics, and ADHD drugs, as well as other medications.
The AmpliChip® CYP450 test can help physicians adjust dosing and select drugs by predicting a phenotype based on a genotype so that patient treatment can be individualised to get the best possible therapeutic results. It can also be used to stratify patients in clinical trials.

Source BioScience is a preferred supplier for Roche AmpliChip® in the UK.

Why use Source BioScience?

  • Quality: Rapid turnaround and accurate results. All data is sent in strictest confidence to you on CD-ROM, e-mail or web server. We are also GLP,GCP ,CPA accredited and a UK preferred service supplier for ABI and Roche.
  • Pricing: Our high throughput reduces unit labour and capital costs meaning we can offer exceptional value for money. Furthermore, savings are made by bulk purchase of reagents.
  • Personal Touch: We can also design, validate and genotype user-defined SNPs.
  • Commitment to improvement: We are continuously introducing new technologies to reduce costs, shorten timelines and reduce consumables including amounts of your DNA.

Top

For further information on SNP genotyping assays available for drug development and metabolism, please click here.

Contact:
Email:   pharma
Telephone:   +44(0)115 973 9012